Researchers have demonstrated that two related enzymes — phosphoinositide-3 kinase gamma and delta — play a key role in the development of T-cell acute lymphoblastic leukemia, a highly aggressive childhood leukemia that is difficult to treat. The study also showed that a dual PI3K gamma/delta inhibitor can significantly prolong survival in a mouse model of the disease.